Regeneron Pharmaceuticals (REGN) concentration risks

The company's concentration profile is shaped by two medium-share exposures that together account for a substantial portion of total revenues. Sanofi collaboration revenue — most of which is attributable to the company's share of profits from the commercialization of Dupixent — represented 41% of total revenues, a dependency exposure: the company relies on its collaboration with Sanofi for the co-commercialization of its largest product, meaning that changes in Sanofi's strategic priorities, cost-sharing terms, or commercial execution could have a direct and significant impact on that revenue stream. Separately, aggregate EYLEA HD and EYLEA net product sales in the United States represented 31% of total revenues, a mixed-character exposure. The product franchise has faced biosimilar competition, making this a situation where the revenue share is medium by disclosed size but the trajectory rather than the current level is the more relevant investment consideration. Together, these two named exposures account for a combined share that approaches the majority of total revenues, concentrating results around a single collaboration partner and a single product franchise. The Dupixent partnership with Sanofi is the larger and more stable of the two by disclosed share, while the EYLEA franchise is the more dynamic one. No geographic, supplier, or customer concentration is disclosed alongside these. The key variables to monitor are Sanofi collaboration terms and Dupixent competitive dynamics, alongside EYLEA franchise volume trends in the face of biosimilar entry.

For the engine’s reasoning on REGN’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.